Elevated prolactin levels in male youths treated with risperidone and quetiapine

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 6, 2005, Pages 893-900

  Stevens, Jonathan R ^a   Kymissis, Paul I ^b   Baker, Amy J L ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Children's Village ^*  (United States)

^c Center for Child Welfare Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PROLACTIN; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGGRESSIVENESS; AMENORRHEA; CHI SQUARE DISTRIBUTION; CHILD; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DOSE RESPONSE; EJACULATION DISORDER; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; IMPULSIVENESS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REPRODUCTION; RETROSPECTIVE STUDY; REVIEW;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; HUMANS; HYPERPROLACTINEMIA; MALE; RESIDENTIAL TREATMENT; RISPERIDONE;

EID: 29944432379     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.893     Document Type: Review

References (26)

1. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL: Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharm 12:83-91, 2002.
2. Armenteros JL, Whitaker AH, Welikson M, Stedge, Gorman J: Risperidone in adolescents with schizophrenia: An open pilot study. J Am Acad Child Adolesc Psychiatry 36(5):694-700, 1997.
3. Bruun RD, Budman CL: Risperidone as a treatment for Tourette syndrome. J Clin Psychiatry 57(1):29-31, 1996.
4. Cesena M, Gonzalez-Heydrich J, Szigethy E, Kohlenberg TM, DeMaso DR: A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharm 12:337-345, 2002.
5. Colao A, Loche S, Cappa M, Di Sarno A, Landi M, Sarnacchiaro F, Facciolli G, Lombardi G: Prolactinomas in children and adolescents: Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777-2780, 1998.
6. Dickson RA, Seeman MV, Corenblum B: Hormonal side effects in women: Typical versus atypical antipsychotic treatment. J Clin Psychiatry 61 (Suppl 8):5-11, 2000.
7. Findling RL, Aman MG, Eerdekens M, Derivan A: Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677-684, 2004.
8. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin re-uptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharm 9(2):115-123, 1999.
9. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S: Risperidone treatment for juvenile bipolar disorder: A retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960-965, 1999.
10. Galli-Tsinopoulou A, Nousia-Arvanitakis S, Mitsiakos G, Karamouzis M, Dimitriadis A: Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab 13:439-441, 2000.
11. Carver DL: Review of quetiapine side effects. J Clin Psychiatry 61(Suppl 8):31-33, 2000.
12. Halbreich U, Kahn LS: Hyperprolactinemia and schizophrenia: Mechanisms and clinical aspects J Psychiatr Prac 9:344-353, 2003.
13. Hardan A, Johnson K, Johnson C: Case study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206-1214, 1996.
14. Holtmann M, Gerstner S, Schmidt MH: Risperidone-associated ejaculatory and urinary dysfunction in male adolescents. J Child Adolesc Psychopharm 13:107-109, 2003.
15. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharm 19:57-61, 1999.
16. Malone RP, Maislin G, Choudhury MS, Muniya S, Gifford, C, Delaney, MA: Risperidone treatment in children and adolescents with autism: Short- and long-term safety and effectiveness. J Am Acad Child Adolesc Psychiatry 41:140-147, 2002.
17. Masi G, Consenza A, Mucci M: Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharm 11:389-394, 2001.
18. McConville B: Quetiapine does not elevate prolactin in adolescents with psychotic disorders. Poster presented at the Annual Meeting of the American Psychiatric Association, Chicago, IL, May 13-18, 2000.
19. McConville B, Arvantis LA, Thyrum PT, Chial Y, Wilkinson LS, Chaney RO, Foster KD, Sorter MT, Freidman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61(4):252-260, 2000.
20. Nasrallah HA, Tandon R: Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 63(Suppl 13):12-20, 2002.
21. Petty RG: Prolactin and antipsychotic medications: Mechanisms of action. Schizophr Res 35(Suppl): S67-S73, 1999.
22. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharm 14:350-358, 2004.
23. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharm 11:415-424, 2001.
24. Smith S: Effects of antipsychotics on sexual and endocrine function in women: Implications for clinical practice. J Clin Psychpharmacol 23:S27-S32, 2003.
25. Turrone P, Kapur S, Seeman MV, Flint AJ: Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133-135, 2002.
26. Wudarksy M, Nicolson R, Hamburger SD, Spechler L, Gochman P, Bedwell J, Lenane MC, Rapoport JL: Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharm 9:239-245, 1999.